Maria Alessandra Calegari

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O⁶-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

Federica Morano, Alessandra Raimondi, Filippo Pagani et al. · Journal of Clinical Oncology · 2022 · 120 citations · Full text

Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer

Ina Valeria Zurlo, Mattia Schino, Antonia Strippoli et al. · Cancer Immunology Immunotherapy · 2021 · 75 citations · Full text

A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

Fotios Loupakis, Rossana Intini, Chiara Cremolini et al. · European Journal of Cancer · 2019 · 69 citations · Full text

Prognostic Biomarkers, Gastrointestinal Oncology, Medicine +7

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation

Maria Alessandra Calegari, Alessandro Inno, Santa Monterisi et al. · British Journal of Cancer · 2017 · 57 citations · Full text

Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report

Armando Orlandi, Romina Fasciani, Alessandra Cassano et al. · BMC Cancer · 2015 · 38 citations · Full text